Merus (MRUS)
(Real Time Quote from BATS)
$53.70 USD
-6.29 (-10.49%)
Updated May 28, 2024 01:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Merus N.V. [MRUS]
Reports for Purchase
Showing records 21 - 40 ( 173 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2Q22: Data from Additional Assets, BLA for Lead Product in the Horizon
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Targeted Bispecific for NRG Cancers. Data Supports Filing With the FDA
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Positive Zeno Update During ASCO ?22 Shapes a Compelling Case for Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Zeno Looks to Shine During ASCO 2022 As Other Biclonics Push Forward; Reit. Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
AACR 2022 Abstract Titles Released (Part II): CGEN, GNTA, MRUS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Bullish on Zeno Update (1H22) Furthering the Chances for Agnostic Label; Reit. Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
HER2xHER3 Bispecific Showed Increased Benefit in Breast Cancer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T